Javier A Menendez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1788867/publications.pdf

Version: 2024-02-01

337	27,143	9264 74	7348 152
papers	citations	h-index	g-index

345	345	345	42308
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin Î±6Î²1 drives endocrine resistance in breast cancer cells. Aging, 2022, 14, .	3.1	3
2	Metformin and Breast Cancer: Where Are We Now?. International Journal of Molecular Sciences, 2022, 23, 2705.	4.1	26
3	Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals, 2022, 15, 19.	3.8	2
4	Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness.. American Journal of Cancer Research, 2022, 12, 839-851.	1.4	0
5	Fatty acid synthase: a druggable driver of breast cancer brain metastasis. Expert Opinion on Therapeutic Targets, 2022, 26, 427-444.	3.4	10
6	Concentration, Propagation and Dilution of Toxic Gases in Underground Excavations under Different Ventilation Modes. International Journal of Environmental Research and Public Health, 2022, 19, 7092.	2.6	8
7	Metformin and breast cancer: an opportunity for pharmacogenetics. Aging, 2022, 14, 5612-5613.	3.1	1
8	Laparoscopic Sleeve Gastrectomy in Patients with Severe Obesity Restores Adaptive Responses Leading to Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences, 2022, 23, 7830.	4.1	4
9	Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General Overview. Biomolecules, 2021, 11, 473.	4.0	10
10	Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. Cancers, 2021, 13, 1132.	3.7	22
11	The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer. Nature Communications, 2021, 12, 1920.	12.8	19
12	TEMPORARY REMOVAL: Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression. Journal of Hepatology, 2021, , .	3.7	3
13	Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals, 2021, 14, 559.	3.8	14
14	Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs. PLoS Computational Biology, 2021, 17, e1008408.	3.2	8
15	Metformin Is a Pyridoxal-5â€²-phosphate (PLP)-Competitive Inhibitor of SHMT2. Cancers, 2021, 13, 4009.	3.7	15
16	Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. Cancers, 2021, 13, 4168.	3.7	8
17	Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. EMBO Molecular Medicine, 2021, 13, e13929.	6.9	6
18	Polyphenols in olive oil: the importance of phenolic compounds in the chemical composition of olive oil. , 2021, , 111-122.		3

#	Article	IF	Citations
19	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death and Disease, 2021, 12, 977.	6.3	33
20	Chemokine (C-C motif) ligand 2 and coronary artery disease: Tissue expression of functional and atypical receptors. Cytokine, 2020, 126, 154923.	3.2	11
21	Plasma metabolic alterations in patients with severe obesity and nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 374-387.	3.7	20
22	Chemokine Câ€“C motif ligand 2 overexpression drives tissue-specific metabolic responses in the liver and muscle of mice. Scientific Reports, 2020, 10, 11954.	3.3	13
23	Structureâ€“Biological Activity Relationships of Extra-Virgin Olive Oil Phenolic Compounds: Health Properties and Bioavailability. Antioxidants, 2020, 9, 685.	5.1	48
24	Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7737.	4.1	6
25	Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7661.	4.1	19
26	Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2â€™-O-Methylation of Viral RNA. Viruses, 2020, 12, 525.	3.3	75
27	Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. Journal of Clinical Medicine, 2020, 9, 1770.	2.4	42
28	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers, 2020, 12, 1757.	3.7	17
29	Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with <scp>PARP</scp> inhibitors. EMBO Molecular Medicine, 2020, 12, e11217.	6.9	37
30	Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology. Frontiers in Oncology, 2020, 10, 620641.	2.8	5
31	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging, 2020, 12, 8-34.	3.1	99
32	The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. Aging, 2020, 12, 4794-4814.	3.1	38
33	Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19. Aging, 2020, 12, 8760-8765.	3.1	38
34	Systemic overexpression of C-C motif chemokine ligand 2 promotes metabolic dysregulation and premature death in mice with accelerated aging. Aging, 2020, 12, 20001-20023.	3.1	5
35	Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer. Aging, 2020, 12, 24671-24692.	3.1	6
36	Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity. Biomolecules, 2020, 10, 780.	4.0	16

#	Article	IF	Citations
37	Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity. Aging, 2020, 12, 21057-21075.	3.1	2
38	Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. Metabolism: Clinical and Experimental, 2019, 99, 81-89.	3.4	43
39	Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A. Nutrients, 2019, 11, 1656.	4.1	26
40	Revisiting silibinin as a novobiocin-like Hsp90â€¯C-terminal inhibitor: Computational modeling and experimental validation. Food and Chemical Toxicology, 2019, 132, 110645.	3.6	16
41	Virgin Olive Oil and Health: Summary of the III International Conference on Virgin Olive Oil and Health Consensus Report, JAEN (Spain) 2018. Nutrients, 2019, 11, 2039.	4.1	116
42	Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. OncoImmunology, 2019, 8, e1633235.	4.6	70
43	Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets. Food and Chemical Toxicology, 2019, 131, 110529.	3.6	15
44	A multiscale model of epigenetic heterogeneity-driven cell fate decision-making. PLoS Computational Biology, 2019, 15, e1006592.	3.2	28
45	Stratification of cancer and diabetes based on circulating levels of formate and glucose. Cancer & Metabolism, 2019, 7, 3.	5.0	23
46	The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin. Frontiers in Oncology, 2019, 9, 193.	2.8	17
47	The moonlighting RNA-binding activity of cytosolic serine hydroxymethyltransferase contributes to control compartmentalization of serine metabolism. Nucleic Acids Research, 2019, 47, 4240-4254.	14.5	32
48	Chemokine (C-C motif) ligand 2 gene ablation protects low-density lipoprotein and paraoxonase-1 double deficient mice from liver injury, oxidative stress and inflammation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1555-1566.	3.8	13
49	The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase. Food and Chemical Toxicology, 2019, 128, 35-45.	3.6	27
50	Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. International Journal of Molecular Sciences, 2019, 20, 1606.	4.1	32
51	Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer. Anti-Cancer Drugs, 2019, 30, 1067-1070.	1.4	5
52	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. Journal of Clinical Medicine, 2019, 8, 2180.	2.4	12
53	An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. Carcinogenesis, 2019, 40, 27-40.	2.8	14
54	Abstract 2746: Stat3 labels a subpopulation of reactive astrocytes required for brain metastasis. , 2019, , .		2

#	Article	IF	Citations
55	Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. Aging, 2019, 11, 2874-2888.	3.1	25
56	In silico clinical trials for anti-aging therapies. Aging, 2019, 11, 6591-6601.	3.1	3
57	Assessment of extracellular matrix-related biomarkers in patients with lower extremity artery disease. Journal of Vascular Surgery, 2018, 68, 1135-1142.e6.	1.1	7
58	Silibinin is a direct inhibitor of STAT3. Food and Chemical Toxicology, 2018, 116, 161-172.	3.6	52
59	Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. Carcinogenesis, 2018, 39, 601-613.	2.8	53
60	Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism. Oncogene, 2018, 37, 963-970.	5.9	85
61	A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. Oncotarget, 2018, 9, 35687-35704.	1.8	55
62	Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. Oncotarget, 2018, 9, 33043-33049.	1.8	13
63	Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation. Frontiers in Endocrinology, 2018, 9, 657.	3.5	85
64	Plasma Energy-Balance Metabolites Discriminate Asymptomatic Patients with Peripheral Artery Disease. Mediators of Inflammation, 2018, 2018, 1-12.	3.0	8
65	Differential inhibitory effect of a pyrazolopyran compound on human serine hydroxymethyltransferase-amino acid complexes. Archives of Biochemistry and Biophysics, 2018, 653, 71-79.	3.0	14
66	Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. Aging Cell, 2018, 17, e12772.	6.7	58
67	Mitostemness. Cell Cycle, 2018, 17, 918-926.	2.6	15
68	STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nature Medicine, 2018, 24, 1024-1035.	30.7	285
69	Epigenetic regulation of cell fate reprogramming in aging and disease: A predictive computational model. PLoS Computational Biology, 2018, 14, e1006052.	3.2	23
70	Treating atherosclerosis: targeting risk factors should not be the only option. Annals of Translational Medicine, 2018, 6, S34-S34.	1.7	2
71	Fatty acid synthase regulates estrogen receptor-Î± signaling in breast cancer cells. Oncogenesis, 2017, 6, e299-e299.	4.9	67
72	Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab. Cell Cycle, 2017, 16, 1022-1028.	2.6	19

#	Article	IF	Citations
73	Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 1001-1016.	3.4	185
74	Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treatment Reviews, 2017, 58, 61-69.	7.7	86
75	EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. Oncology Reports, 2017, 38, 263-270.	2.6	11
76	Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study. International Journal of Molecular Sciences, 2017, 18, 2263.	4.1	18
77	Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users. Nutrients, 2017, 9, 121.	4.1	33
78	Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer. Frontiers in Cell and Developmental Biology, 2017, 5, 49.	3.7	23
79	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. Oncotarget, 2017, 8, 99223-99236.	1.8	9
80	Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. Histology and Histopathology, 2017, 32, 687-698.	0.7	40
81	BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. Oncotarget, 2017, 8, 35019-35032.	1.8	12
82	The practice-changing QUARTZ trial: is there any role for whole brain radiotherapy in patients with non-small cell lung cancer and brain metastases?. Translational Cancer Research, 2017, 6, S201-S204.	1.0	2
83	Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget, 2016, 7, 32006-32014.	1.8	47
84	Nuclear reprogramming of cancer stem cells: Corrupting the epigenetic code of cell identity with oncometabolites. Molecular and Cellular Oncology, 2016, 3, e1160854.	0.7	3
85	Epigenetics and nutrition-related epidemics of metabolic diseases: Current perspectives and challenges. Food and Chemical Toxicology, 2016, 96, 191-204.	3.6	27
86	STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. Cell Cycle, 2016, 15, 3413-3418.	2.6	49
87	Metformin targets histone acetylation in cancer-prone epithelial cells. Cell Cycle, 2016, 15, 3355-3361.	2.6	17
88	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
89	Oncometabolic Nuclear Reprogramming of Cancer Stemness. Stem Cell Reports, 2016, 6, 273-283.	4.8	34
90	Exploring the Process of Energy Generation in Pathophysiology by Targeted Metabolomics: Performance of a Simple and Quantitative Method. Journal of the American Society for Mass Spectrometry, 2016, 27, 168-177.	2.8	35

#	Article	IF	Citations
91	Mitophagy-driven mitochondrial rejuvenation regulates stem cell fate. Aging, 2016, 8, 1330-1352.	3.1	70
92	Activation of the methylation cycle in cells reprogrammed into a stem cell-like state. Oncoscience, 2016, 2, 958-967.	2.2	30
93	The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells. Oncoscience, 2016, 3, 242-257.	2.2	19
94	Metformin and cancer: Quo vadis et cui bono?. Oncotarget, 2016, 7, 54096-54101.	1.8	15
95	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget, 2016, 7, 82185-82199.	1.8	16
96	Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome. Oncotarget, 2016, 7, 11959-11971.	1.8	9
97	Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer. Oncotarget, 2016, 7, 71151-71168.	1.8	40
98	Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based â€œstarvationâ€•strategies in BRCA1 carriers. Oncotarget, 2016, 7, 52974-52992.	1.8	26
99	An improved axillary staging system using the OSNA assay does not modify the therapeutic management of breast cancer patients. Scientific Reports, 2015, 4, 5743.	3.3	2
100	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget, 2015, 6, 32317-32338.	1.8	35
101	Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like Cells. PLoS ONE, 2015, 10, e0137800.	2.5	28
102	Metabolic control of cancer cell stemness: Lessons from iPS cells. Cell Cycle, 2015, 14, 3801-3811.	2.6	37
103	Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. Cancer Treatment Reviews, 2015, 41, 540-546.	7.7	124
104	The Promiscuous and Synergic Molecular Interaction of Polyphenols in Bactericidal Activity: An Opportunity to Improve the Performance of Antibiotics?. Phytotherapy Research, 2015, 29, 466-473.	5.8	34
105	The acute impact of polyphenols from Hibiscus sabdariffa in metabolic homeostasis: an approach combining metabolomics and gene-expression analyses. Food and Function, 2015, 6, 2957-2966.	4.6	25
106	Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties. Cell Cycle, 2015, 14, 3527-3532.	2.6	25
107	Blockade of a Key Region in the Extracellular Domain Inhibits HER2 Dimerization and Signaling. Journal of the National Cancer Institute, 2015, 107, djv090.	6.3	10
108	Recommendations of the Spanish Brachytherapy Group of SEOR for HDR endoluminal treatments. Part 1: Oesophagus. Clinical and Translational Oncology, 2015, 17, 581-589.	2.4	4

#	Article	IF	Citations
109	Lemon verbena (Lippia citriodora) polyphenols alleviate obesity-related disturbances in hypertrophic adipocytes through AMPK-dependent mechanisms. Phytomedicine, 2015, 22, 605-614.	5.3	61
110	Managing Hypertension by Polyphenols. Planta Medica, 2015, 81, 624-629.	1.3	18
111	A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111 In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. Nuclear Medicine and Biology, 2015, 42, 931-938.	0.6	14
112	Pediatric solid organ transplant recipients: Transition to home and chronic illness care. Pediatric Transplantation, 2015, 19, 118-129.	1.0	54
113	Mapping of the circulating metabolome reveals Î±-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease. International Journal of Obesity, 2015, 39, 279-287.	3.4	77
114	Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer. Oncotarget, 2015, 6, 7104-7122.	1.8	17
115	Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget, 2015, 6, 12279-12296.	1.8	53
116	Heregulin, a new interactor of the telosome/shelterin complex in human telomeres. Oncotarget, 2015, 6, 39408-39421.	1.8	5
117	Heregulin, a new regulator of telomere length in human cells. Oncotarget, 2015, 6, 39422-39436.	1.8	8
118	The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs. Current Pharmaceutical Design, 2015, 21, 3644-3653.	1.9	16
119	Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology. World Journal of Gastroenterology, 2015, 21, 7529.	3.3	35
120	Understanding the role of circulating chemokine (C-C motif) ligand 2 in patients with chronic ischemia threatening the lower extremities. Vascular Medicine, 2014, 19, 442-451.	1.5	11
121	Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle, 2014, 13, 1132-1144.	2.6	57
122	Autophagy Is an Inflammation-Related Defensive Mechanism Against Disease. Advances in Experimental Medicine and Biology, 2014, 824, 43-59.	1.6	34
123	Xenopatients 2.0: Reprogramming the epigenetic landscapes of patient-derived cancer genomes. Cell Cycle, 2014, 13, 358-370.	2.6	14
124	Hibiscus sabdariffa extract lowers blood pressure and improves endothelial function. Molecular Nutrition and Food Research, 2014, 58, 1374-1378.	3.3	52
125	Energy Metabolism and Metabolic Sensors in Stem Cells: The Metabostem Crossroads of Aging and Cancer. Advances in Experimental Medicine and Biology, 2014, 824, 117-140.	1.6	24
126	Gerometabolites: The pseudohypoxic aging side of cancer oncometabolites. Cell Cycle, 2014, 13, 699-709.	2.6	33

#	Article	IF	Citations
127	Metabostemness: A New Cancer Hallmark. Frontiers in Oncology, 2014, 4, 262.	2.8	95
128	The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential. Frontiers in Oncology, 2014, 4, 308.	2.8	17
129	CCN1 promotes vascular endothelial growth factor secretion through Î±_vÎ²₃ integrin receptors in breast cancer. Journal of Cell Communication and Signaling, 2014, 8, 23-27.	3.4	11
130	Polyphenols and the Modulation of Gene Expression Pathways: Can We Eat Our Way Out of the Danger of Chronic Disease?. Critical Reviews in Food Science and Nutrition, 2014, 54, 985-1001.	10.3	91
131	Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. Lung Cancer, 2014, 86, 102-104.	2.0	27
132	Molecular Promiscuity of Plant Polyphenols in the Management of Age-Related Diseases: Far Beyond Their Antioxidant Properties. Advances in Experimental Medicine and Biology, 2014, 824, 141-159.	1.6	77
133	Cell Cycle Regulation by the Nutrient-Sensing Mammalian Target of Rapamycin (mTOR) Pathway. Methods in Molecular Biology, 2014, 1170, 113-144.	0.9	108
134	Computer-aided discovery of biological activity spectra for anti-aging and anti-cancer olive oil oleuropeins. Aging, 2014, 6, 731-741.	3.1	29
135	Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions. Oncoscience, 2014, 1, 803-806.	2.2	31
136	Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics. Oncotarget, 2014, 5, 1942-1954.	1.8	14
137	Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget, 2014, 5, 2344-2348.	1.8	40
138	Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget, 2014, 5, 8306-8316.	1.8	94
139	The nutritional phenome of EMT-induced cancer stem-like cells. Oncotarget, 2014, 5, 3970-3982.	1.8	61
140	Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient. Anticancer Research, 2014, 34, 4323-7.	1.1	21
141	A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study. AIDS Research and Therapy, 2013, 10, 11.	1.7	12
142	Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food and Chemical Toxicology, 2013, 60, 360-368.	3.6	53
143	Multifunctional targets of dietary polyphenols in disease: A case for the chemokine network and energy metabolism. Food and Chemical Toxicology, 2013, 51, 267-279.	3.6	55
144	Identification of active compounds in vegetal extracts based on correlation between activity and HPLCâ€“MS data. Food Chemistry, 2013, 136, 392-399.	8.2	13

#	Article	IF	Citations
145	Metabolic stress in infected cells may represent a therapeutic target for human immunodeficiency virus infection. Medical Hypotheses, 2013, 81, 125-130.	1.5	6
146	The mitochondrial H⁺-ATP synthase and the lipogenic switch. Cell Cycle, 2013, 12, 207-218.	2.6	77
147	The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. Cell Cycle, 2013, 12, 1166-1179.	2.6	146
148	Autophagy in stem cells. Autophagy, 2013, 9, 830-849.	9.1	255
149	The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer. Scientific Reports, 2013, 3, 2469.	3.3	97
150	Mitochondrial Dysfunction: A Basic Mechanism in Inflammation-Related Non-Communicable Diseases and Therapeutic Opportunities. Mediators of Inflammation, 2013, 2013, 1-13.	3.0	116
151	Ubiquitous Transgenic Overexpression of C-C Chemokine Ligand 2: A Model to Assess the Combined Effect of High Energy Intake and Continuous Low-Grade Inflammation. Mediators of Inflammation, 2013, 2013, 1-19.	3.0	13
152	Basal/HER2 breast carcinomas. Cell Cycle, 2013, 12, 225-245.	2.6	48
153	Mammosphere Formation in Breast Carcinoma Cell Lines Depends upon Expression of E-cadherin. PLoS ONE, 2013, 8, e77281.	2.5	171
154	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Scientific Reports, 2013, 3, 2560.	3.3	74
155	Metformin: a cheap and wellâ€tolerated drug that provides benefits for viral infections. HIV Medicine, 2013, 14, 233-240.	2.2	16
156	Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells. Cell Cycle, 2013, 12, 3471-3477.	2.6	37
157	Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil. Cell Cycle, 2013, 12, 555-578.	2.6	131
158	Stem cell-like ALDH^{bright}cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle, 2013, 12, 3390-3404.	2.6	65
159	Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Scientific Reports, 2013, 3, 2459.	3.3	67
160	Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle, 2013, 12, 3109-3124.	2.6	90
161	Serine79-phosphorylated acetyl-CoA carboxylase, a downstream target of AMPK, localizes to the mitotic spindle poles and the cytokinesis furrow. Cell Cycle, 2013, 12, 1639-1641.	2.6	17
162	Synchronous solid neuroendocrine breast carcinoma and abdominal lymphoma: A case report and review of the literature. Oncology Letters, 2013, 5, 459-462.	1.8	4

#	Article	IF	Citations
163	One-carbon metabolism: An aging-cancer crossroad for the gerosuppressant metformin. Aging, 2013, 4, 894-898.	3.1	20
164	Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget, 2013, 4, 1484-1495.	1.8	31
165	Polo-like kinase 1 directs the AMPK-mediated activation of myosin regulatory light chain at the cytokinetic cleavage furrow independently of energy balance. Cell Cycle, 2012, 11, 2422-2426.	2.6	16
166	AMPK: A bona fide resident of the mitotic spindle midzone. Cell Cycle, 2012, 11, 841-842.	2.6	5
167	Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle, 2012, 11, 4020-4032.	2.6	119
168	Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. British Journal of Cancer, 2012, 106, 1406-1414.	6.4	42
169	Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205. Cell Cycle, 2012, 11, 1235-1246.	2.6	56
170	Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. Oncology Reports, 2012, 27, 1887-92.	2.6	5
171	Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. International Journal of Oncology, 2012, 41, 1128-1138.	3.3	50
172	Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle, 2012, 11, 2782-2792.	2.6	116
173	Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Scientific Reports, 2012, 2, 964.	3.3	55
174	Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis. Cell Cycle, 2012, 11, 4211-4221.	2.6	18
175	Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle, 2012, 11, 865-870.	2.6	37
176	Plant-derived polyphenols regulate expression of miRNA paralogs miR-103/107 and miR-122 and prevent diet-induced fatty liver disease in hyperlipidemic mice. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 894-899.	2.4	117
177	Phenolic Secoiridoids in Extra Virgin Olive Oil Impede Fibrogenic and Oncogenic Epithelial-to-Mesenchymal Transition: Extra Virgin Olive Oil As a Source of Novel Antiaging Phytochemicals. Rejuvenation Research, 2012, 15, 3-21.	1.8	36
178	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
179	Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle, 2012, 11, 974-989.	2.6	94
180	Rejuvenating regeneration: Metformin activates endogenous adult stem cells. Cell Cycle, 2012, 11, 3521-3522.	2.6	20

#	Article	IF	Citations
181	Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging, 2012, 4, 480-498.	3.1	104
182	Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget, 2012, 3, 1600-1614.	1.8	73
183	Uptake and metabolism of olive oil polyphenols in human breast cancer cells using nano-liquid chromatography coupled to electrospray ionizationâ€“time of flight-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 898, 69-77.	2.3	30
184	Synergism of plant-derived polyphenols in adipogenesis: Perspectives and implications. Phytomedicine, 2012, 19, 253-261.	5.3	122
185	Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Investigational New Drugs, 2012, 30, 846-852.	2.6	11
186	Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: New insight into the role of mitophagy in cell stemness. Aging, 2012, 4, 393-401.	3.1	104
187	Metformin-induced preferential killing of breast cancer initiating CD44+CD24â^'/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget, 2012, 3, 395-398.	1.8	134
188	Expression status of the autophagyâ€regulatory gene ATG6/BECN1 in ERBB2â€positive breast carcinomas: Bypassing ERBB2â€induced oncogenic senescence to regulate the efficacy of ERBB2â€targeted therapies. Genes Chromosomes and Cancer, 2011, 50, 284-290.	2.8	9
189	Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resistance Updates, 2011, 14, 212-223.	14.4	58
190	Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. Biochemical and Biophysical Research Communications, 2011, 407, 412-419.	2.1	44
191	Serum fatty acid synthase concentration is increased in patients with hepatitis viral infection and may assist in the prediction of liver steatosis. Journal of Clinical Virology, 2011, 51, 199-201.	3.1	19
192	Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib. Breast Cancer Research, 2011, 13, 401.	5.0	3
193	Metformin: Multi-faceted protection against cancer. Oncotarget, 2011, 2, 896-917.	1.8	263
194	Gerosuppressant Metformin: less is more. Aging, 2011, 3, 348-362.	3.1	56
195	Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (ErbituxÃ¯Â¿Â½) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. International Journal of Oncology, 2011, 39, 1455-79.	3.3	15
196	Continuous administration of polyphenols from aqueous rooibos (Aspalathus linearis) extract ameliorates dietary-induced metabolic disturbances in hyperlipidemic mice. Phytomedicine, 2011, 18, 414-424.	5.3	79
197	mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: A roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle, 2011, 10, 3658-3677.	2.6	132
198	Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs). Cell Cycle, 2011, 10, 3140-3152.	2.6	32

#	Article	IF	Citations
199	The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Research and Treatment, 2011, 126, 355-364.	2.5	173
200	Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast. Breast Cancer Research and Treatment, 2011, 126, 241-245.	2.5	6
201	Direct antitumour activity of zoledronic acid: preclinical and clinical data. Clinical and Translational Oncology, 2011, 13, 148-155.	2.4	16
202	Antibody microarrayâ€based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma. Journal of Surgical Oncology, 2011, 104, 106-109.	1.7	6
203	Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2â€driven cancer cell growth. Journal of Cellular Physiology, 2011, 226, 52-57.	4.1	28
204	Stem cell property epithelialâ€toâ€mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbituxâ„¢) efficacy in KRAS wildâ€type tumor cells. Journal of Cellular Biochemistry, 2011, 112, 10-29.	2.6	41
205	Autophagy positively regulates the CD44⁺CD24^{-/low}breast cancer stem-like phenotype. Cell Cycle, 2011, 10, 3871-3885.	2.6	172
206	Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3. International Journal of Oncology, 2011, 38, 1533-47.	3.3	28
207	Metformin activates an Ataxia Telangiectasia Mutated (ATM)/Chk2-regulated DNA damage-like response. Cell Cycle, 2011, 10, 1499-1501.	2.6	72
208	Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. Cell Cycle, 2011, 10, 1295-1302.	2.6	50
209	Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFÎ²-induced oncomiR miRNA-181a. Cell Cycle, 2011, 10, 1144-1151.	2.6	108
210	Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer. Aging, 2011, 3, 1063-1077.	3.1	70
211	The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncology Reports, 2011, 25, 135-40.	2.6	34
212	Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells. Current Molecular Medicine, 2010, 10, 674-691.	1.3	52
213	Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: New insights into de novo resistance to trastuzumab (Herceptin). International Journal of Oncology, 2010, 37, 669-78.	3.3	46
214	Qualitative screening of phenolic compounds in olive leaf extracts by hyphenated liquid chromatography and preliminary evaluation of cytotoxic activity against human breast cancer cells. Analytical and Bioanalytical Chemistry, 2010, 397, 643-654.	3.7	119
215	Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss. Nutrition and Metabolism, 2010, 7, 14.	3.0	13
216	Characterization and quantification of phenolic compounds of extra-virgin olive oils with anticancer properties by a rapid and resolutive LC-ESI-TOF MS method. Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 416-429.	2.8	132

#	Article	IF	Citations
217	Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection. BMC Gastroenterology, 2010, 10, 92.	2.0	18
218	Quantitative and functional influence of surround luminance on the letter contrast sensitivity function. Ophthalmic and Physiological Optics, 2010, 30, 188-199.	2.0	8
219	Thyroid hormone responsive Spot 14 increases during differentiation of human adipocytes and its expression is down-regulated in obese subjects. International Journal of Obesity, 2010, 34, 487-499.	3.4	32
220	Discordant expression of molecular markers between primary and nodal metastases: a histopathological manifestation of the â€˜self (stem cell)-seedingâ€™ nature of breast cancer disease?. Annals of Oncology, 2010, 21, 901-902.	1.2	2
221	Metformin against TGFÎ²-induced epithelial-to-mesenchymal transition (EMT): From cancer stem cells to aging-associated fibrosis. Cell Cycle, 2010, 9, 4461-4468.	2.6	202
222	Extracellular Fatty Acid Synthase: A Possible Surrogate Biomarker of Insulin Resistance. Diabetes, 2010, 59, 1506-1511.	0.6	47
223	Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinicalâ€“translational research experience at the Catalan Institute of Oncology. Annals of Oncology, 2010, 21, 187-189.	1.2	60
224	Metformin: a pharmacological approach integrating hyperinsulinemia breast cÃ¡ncer at the molecular, cellular clinical levels. Avances En DiabetologÃa, 2010, 26, 79-94.	0.1	0
225	Prediction of Extra Virgin Olive Oil Varieties through Their Phenolic Profile. Potential Cytotoxic Activity against Human Breast Cancer Cells. Journal of Agricultural and Food Chemistry, 2010, 58, 9942-9955.	5.2	82
226	Pharmacological Mimicking of Caloric Restriction Elicits Epigenetic Reprogramming of Differentiated Cells to Stem-Like Self-Renewal States. Rejuvenation Research, 2010, 13, 519-526.	1.8	14
227	Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle, 2010, 9, 1057-1064.	2.6	205
228	Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: Molecular mechanisms and therapeutic perspectives. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 381-391.	2.4	126
229	Dynamic emergence of the mesenchymal CD44posCD24neg/low phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochemical and Biophysical Research Communications, 2010, 397, 27-33.	2.1	60
230	Olive oil and health: Summary of the II international conference on olive oil and health consensus report, JaÃ©n and CÃ³rdoba (Spain) 2008. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 284-294.	2.6	449
231	Polyphenols in Olive Oil. , 2010, , 167-175.		14
232	Metformin regulates breast cancer stem cello ntogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle, 2010, 9, 3831-3838.	2.6	179
233	Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contrast mitosis marker in breast cancer core biopsies. International Journal of Oncology, 2010, 36, 107-15.	3.9	6
234	Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle, 2010, 9, 3807-14.	2.6	107

#	Article	IF	Citations
235	Fatty Acid Synthase: Association with Insulin Resistance, Type 2 Diabetes, and Cancer. Clinical Chemistry, 2009, 55, 425-438.	3.2	175
236	The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle, 2009, 8, 88-96.	2.6	238
237	The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Annals of Oncology, 2009, 20, 592-595.	1.2	50
238	Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, aurorasandpolo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle, 2009, 8, 1633-1636.	2.6	54
239	Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1097-9.	2.3	7
240	AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. Cell Cycle, 2009, 8, 3679-3683.	2.6	70
241	Mitotic kinase dynamics of the active form of AMPK (Phospho-AMPKÎ±Thr172) in human cancer cells. Cell Cycle, 2009, 8, 788-791.	2.6	55
242	The active form of the metabolic sensor AMP-activated protein kinase Î± (AMPKÎ±) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. Cell Cycle, 2009, 8, 2385-2398.	2.6	94
243	If Mammalian Target of Metformin Indirectly Is Mammalian Target of Rapamycin, Then the Insulin-Like Growth Factor-1 Receptor Axis Will Audit the Efficacy of Metformin in Cancer Clinical Trials. Journal of Clinical Oncology, 2009, 27, e207-e209.	1.6	32
244	A 2â€Dâ€HPLCâ€CE platform coupled to ESIâ€TOFâ€MS to characterize the phenolic fraction in olive oil. Electrophoresis, 2009, 30, 2688-2701.	2.4	32
245	Direct characterization of aqueous extract of Hibiscus sabdariffa using HPLC with diode array detection coupled to ESI and ion trap MS. Journal of Separation Science, 2009, 32, 3441-3448.	2.5	93
246	mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (TykerbÂ®). Clinical and Translational Oncology, 2009, 11, 455-459.	2.4	58
247	Characterization of isomers of oleuropein aglycon in olive oils by rapidâ€resolution liquid chromatography coupled to electrospray timeâ€ofâ€flight and ion trap tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2009, 23, 51-59.	1.5	46
248	Val1483Ile in FASN Gene Is Linked to Central Obesity and Insulin Sensitivity in Adult White Men. Obesity, 2009, 17, 1755-1761.	3.0	15
249	Tentative Characterization of Novel Phenolic Compounds in Extra Virgin Olive Oils by Rapid-Resolution Liquid Chromatography Coupled with Mass Spectrometry. Journal of Agricultural and Food Chemistry, 2009, 57, 11140-11147.	5.2	42
250	AMPK-sensed cellular energy state regulates the release of extracellular Fatty Acid Synthase. Biochemical and Biophysical Research Communications, 2009, 378, 488-493.	2.1	22
251	The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells. Biochemical and Biophysical Research Communications, 2009, 380, 638-643.	2.1	23
252	Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients. International Journal of Oncology, 2009, 35, 1369-76.	3.3	19

#	Article	IF	Citations
253	Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab. PLoS ONE, 2009, 4, e6251.	2.5	206
254	Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2. International Journal of Oncology, 2009, 34, 43-51.	3.3	13
255	Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Research and Treatment, 2008, 109, 471-479.	2.5	98
256	Giacomo Castelvetroâ€™s salads. Anti-HER2 oncogene nutraceuticals since the 17th century?. Clinical and Translational Oncology, 2008, 10, 30-34.	2.4	17
257	An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 10, 219-226.	2.4	0
258	BRCA1 and acetylâ€CoA carboxylase: The metabolic syndrome of breast cancer. Molecular Carcinogenesis, 2008, 47, 157-163.	2.7	65
259	The tyrosine kinase receptor HER2 (erbBâ€2): From oncogenesis to adipogenesis. Journal of Cellular Biochemistry, 2008, 105, 1147-1152.	2.6	29
260	ATM germline mutations in Spanish earlyâ€onset breast cancer patients negative for BRCA1/BRCA2 mutations. Clinical Genetics, 2008, 73, 465-473.	2.0	19
261	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Proliferation, 2008, 41, 59-85.	5.3	160
262	tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO). BMC Cancer, 2008, 8, 377.	2.6	108
263	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (TykerbÂ®) in human breast carcinoma cells. Annals of Oncology, 2008, 19, 1097-1109.	1.2	39
264	Her-2/neu-induced â€œCytokine Signatureâ€•in Breast Cancer. Advances in Experimental Medicine and Biology, 2008, 617, 311-319.	1.6	16
265	Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays. International Journal of Molecular Medicine, 2008, 22, 433-9.	4.0	60
266	Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncology Reports, 2008, 20, 1369-74.	2.6	92
267	Targeting Human Epidermal Growth Factor Receptor 2: It Is Time to Kill Kinase Death Human Epidermal Growth Factor Receptor 3. Journal of Clinical Oncology, 2007, 25, 2496-2498.	1.6	6
268	Testing the Efficacy of Antiangiogenic Agents in Advanced Neuroendocrine Tumors. Journal of Clinical Oncology, 2007, 25, 2624-2624.	1.6	0
269	Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Oncology Reports, 2007, 18, 973.	2.6	24
270	Pharmacological blockade of Fatty Acid Synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptinâ„¢) by transcriptionally inhibiting â€˜HER2 super-expressionâ€™ occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. International Journal of Oncology, 2007, 31, 769.	3.3	15

#	Article	IF	Citations
271	Protein array technology to detect HER2 (erbB-2)-induced â€˜cytokine signatureâ€™ in breast cancer. European Journal of Cancer, 2007, 43, 1117-1124.	2.8	83
272	Mapping Protein-Protein Interactions for the Yeast ABC Transporter Ycf1p by Integrated Split-Ubiquitin Membrane Yeast Two-Hybrid Analysis. Molecular Cell, 2007, 26, 15-25.	9.7	102
273	Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?. Breast Cancer Research, 2007, 9, 111.	5.0	19
274	Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Reviews Cancer, 2007, 7, 763-777.	28.4	2,355
275	Up-regulation of Î±VÎ²3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner. Differentiation, 2007, 75, 819-830.	1.9	31
276	Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptinâ„¢) in HER2-overexpressing breast cancer cells. BMC Cancer, 2007, 7, 80.	2.6	154
277	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). International Journal of Molecular Medicine, 2007, 20, 3-10.	4.0	96
278	Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to		

#	Article	IF	Citations
289	Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?. Current Pharmaceutical Biotechnology, 2006, 7, 483-494.	1.6	163
290	Mediterranean Dietary Traditions for the Molecular Treatment of Human Cancer: Anti-Oncogenic Actions of the Main Olive Oils Monounsaturated Fatty Acid Oleic Acid (18:1n-9). Current Pharmaceutical Biotechnology, 2006, 7, 495-502.	1.6	88
291	Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression. Journal of Clinical Oncology, 2006, 24, 3735-3746.	1.6	68
292	DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. International Journal of Molecular Medicine, 2006, 18, 1081-7.	4.0	10
293	Orlistat: From Antiobesity Drug to Anticancer Agent in Her-2/neu (erbB-2)-Overexpressing Gastrointestinal Tumors?. Experimental Biology and Medicine, 2005, 230, 151-154.	2.4	24
294	Exogenous supplementation with Ï‰-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. European Journal of Cancer Prevention, 2005, 14, 263-270.	1.3	84
295	Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptinâ„¢) in breast cancer cells with Her-2/neu oncogene amplification. Annals of Oncology, 2005, 16, 359-371.	1.2	197
296	A novel CYR61-triggered â€˜CYR61-Î±vÎ²3 integrin loopâ€™ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene, 2005, 24, 761-779.	5.9	138
297	Î±VÎ²3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene, 2005, 24, 3759-3773.	5.9	93
298	In support of fatty acid synthase (FAS) as a metabolic oncogene: Extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. Journal of Cellular Biochemistry, 2005, 94, 1-4.	2.6	77
299	Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1? (HIF-1?)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene. Journal of Cellular Biochemistry, 2005, 94, 857-863.	2.6	28
300	Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. International Journal of Cancer, 2005, 115, 19-35.	5.1	100
301	Effect of Î³-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene. Journal of the National Cancer Institute, 2005, 97, 1611-1615.	6.3	36
302	Growth and Molecular Interactions between Tamoxifen and Trastuzumab. Clinical Cancer Research, 2005, 11, 3597-3597.	7.0	0
303	Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. International Journal of Oncology, 2005, 26, 649.	3.3	5
304	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. International Journal of Oncology, 2005, 26, 1507.	3.3	5
305	RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. International Journal of Molecular Medicine, 2005, 15, 33.	4.0	12
306	Antitumoral actions of the anti-obesity drug orlistat (Xenicalâ„¢) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Annals of Oncology, 2005, 16, 1253-1267.	1.2	144

#	Article	IF	Citations
307	Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of Î³-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwoâ€™s hypothesis. Medical Hypotheses, 2005, 64, 337-341.	1.5	23
308	Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?. Medical Hypotheses, 2005, 64, 342-349.	1.5	62
309	Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Medical Hypotheses, 2005, 64, 997-1001.	1.5	72
310	Obesity, fatty acid synthase, and cancer: serendipity or forgotten causal linkage?. Molecular Genetics and Metabolism, 2005, 84, 293-295.	1.1	16
311	Targeting Fatty Acid Synthase: Potential for Therapeutic Intervention in Her-2/neu-Overexpressing Breast Cancer. Drug News and Perspectives, 2005, 18, 375.	1.5	66
312	RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. International Journal of Molecular Medicine, 2005, 15, 33-40.	4.0	20
313	Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. International Journal of Oncology, 2005, 26, 649-59.	3.3	7
314	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. International Journal of Oncology, 2005, 26, 1507-15.	3.3	9
315	Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells. Annals of Oncology, 2004, 15, 1719-1721.	1.2	25
316	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-Î²B. International Journal of Oncology, 2004, 24, 591.	3.3	36
317	Inhibition of fatty acid synthase (FAS) suppressesHER2/neu(erbB-2) oncogene overexpression in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10715-10720.	7.1	297
318	Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene, 2004, 23, 4945-4958.	5.9	36
319	Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells to Docetaxel (taxotere). Breast Cancer Research and Treatment, 2004, 84, 183-195.	2.5	71
320	Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma. Breast Cancer Research and Treatment, 2004, 86, 125-137.	2.5	47
321	?-6 Polyunsaturated fatty acid ?-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: ?-Linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells. International Journal of Cancer, 2004, 109, 949-954.	5.1	22
322	Pharmacological inhibition of fatty acid synthase (FAS): A novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Molecular Carcinogenesis, 2004, 41, 164-178.	2.7	71
323	Ï‰-6 polyunsaturated fatty acid Î³-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Oncology Reports, 2004, 11, 1241.	2.6	16
324	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. International Journal of Oncology, 2004, 24, 591-608.	3.3	41

#	Article	IF	Citations
325	Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Oncology Reports, 2004, 11, 1241-52.	2.6	43
326	Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 717 but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. International Journal of Oncology, 2004, 24, 1369-83.	3.3	26
327	Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncology Reports, 2004, 12, 411-22.	2.6	29
328	Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Archivum Immunologiae Et Therapiae Experimentalis, 2004, 52, 414-26.	2.3	37
329	The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives.. Endocrine-Related Cancer, 2003, 10, 141-152.	3.1	103
330	Effects of a high olive oil diet on the clinical behavior and histopathological features of rat DMBA-induced mammary tumors compared with a high corn oil diet. International Journal of Oncology, 2002, 21, 745.	3.3	26
331	Synergistic Interaction Between Vinorelbine and Gamma-Linolenic Acid in Breast Cancer Cells. Breast Cancer Research and Treatment, 2002, 72, 203-219.	2.5	68
332	Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. European Journal of Cancer, 2001, 37, 402-413.	2.8	124
333	Solid neuroendocrine breast carcinomas: Incidence, clinico-pathological features and immunohistochemical profiling. Oncology Reports, 1994, 20, 1369.	2.6	46
334	Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: Relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2. International Journal of Oncology, 1992, 34, 43.	3.3	17
335	Growth and molecular interactions of the anti-EGFR antibody Cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: New prospects in the treatment of triple-negative/basal-like breast cancer. International Journal of Oncology, 1992, 33, 1165.	3.3	14
336	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressaâ„¢)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). International Journal of Molecular Medicine, 0, , .	4.0	31
337	Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling. International Journal of Oncology, 0, , .	3.3	14